News about Market

Sunshine Biopharma's Canadian subsidiary Nora Pharma Launches Generic Cholesterol Drug Pravastatin

Sunshine Biopharma’s wholly owned Canadian subsidiary, Nora Pharma, has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid Metabolism Regulators.

Market | 17/10/2025 | By Dineshwori |  260

Rubicon Research Listed on NSE

Mumbai-based pharmaceutical formulations company Rubicon Research Ltd has been officially listed on the National Stock Exchange (NSE).

Market | 16/10/2025 | By Dineshwori |  333

India's Drugs & Pharmaceuticals Exports Continue Upward Trend in September 2025

India’s drugs and pharmaceuticals exports rose by 2.56 percent, reaching USD 2.62 billion in September 2025, up from USD 2.56 billion in the same month last year, according to the latest data from the Ministry of Commerce & Industry.

Market | 16/10/2025 | By Dineshwori |  1283

Syngene International Invests in Peptide Laboratory and Advanced Automation

Syngene International has set up a dedicated peptide laboratory equipped with advanced automation technologies to accelerate hit-to-lead timelines. The investment enhances the company’s integrated drug discovery and development capabilities, reinforcing its position as a leading partner for end-to-end research solutions.

Market | 16/10/2025 | By Dineshwori |  312

AstraZeneca India to Launch Hyperkalaemia Treatment Lokelma in November 2025

AstraZeneca Pharma India Limited (AZPIL) has announced the upcoming launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India in November 2025.

Market | 15/10/2025 | By Dineshwori |  1053

BioCryst Strengthens Rare-Disease Portfolio with USD 700 Million Acquisition of Astria

Under the terms of the agreement, Astria shareholders will receive USD 8.55 per share in cash along with 0.59 BioCryst shares for each Astria share, representing a premium of about fifty-four percent over Astria’s previous closing price.

Market | 15/10/2025 | By Darshana |  188

MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients

The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.

Market | 14/10/2025 | By Dineshwori |  582

Cadila Pharmaceuticals Introduces Dlorfast-M Tablets to Treat Allergic Rhinitis and Urticaria

Allergic rhinitis and urticaria are chronic health conditions that affect millions of people globally. Cadila Pharmaceuticals has introduced Dlorfast-M as a dual-action therapy targeting two pathways of the allergic response—histamine and leukotriene—aiming to provide wider and more effective symptom management.

Market | 14/10/2025 | By Dineshwori |  285

Bristol Myers Squibb Acquires Orbital Therapeutics

The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.

Market | 13/10/2025 | By Dineshwori |  254

Smartee Denti-Technology Launches Innovative Sleep Aligners to Treat Sleep Apnoea and Snoring

Chinese dental technology company Smartee Denti-Technology has announced the global launch of its Smartee Sleep Aligners, a new clear aligner series designed to manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS).

Market | 13/10/2025 | By Dineshwori |  135